BioXcel Therapeutics Appoints Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations

Support preparation and implementation of proof of concept and registration trials for two lead clinical program

BRANFORD, Conn., Sept. 04, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the appointment of Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations, effectively immediately.

Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, commented, “David possesses a wealth of knowledge and expertise in drug development, clinical and commercial manufacturing, and supply chain management which will be instrumental in the success of our clinical programs, BXCL501 and BXCL701, as well as setting the stage for our commercial operations. David represents another important addition to our world-class leadership team. I am confident that his contributions will be important for future milestones related to our current development candidates and our emerging pipeline in neuroscience and immuno-oncology.”

“I am excited to join BTI and to lead the pharmaceutical development and operational efforts for its impressive clinical and preclinical pipeline,” commented Dr. Hanley. “I look forward to identifying and executing on the product development opportunities through all stages to maximize the potential of our programs and to have a positive impact on the lives of patients in need.”

Dr. Hanley has 17 years of experience in Chemistry, Manufacturing and Controls (CMC) and Technical Operations functions and cross-functional development teams in the U.S. and Europe. Most recently, Dr. Hanley was the Vice President of Pharmaceutical Sciences at Radius Health Inc. (NASDAQ: RDUS), subsequent to serving as Executive Director of Technical Operations, where he was responsible for technical development, CMC Regulatory approval and a successful commercial launch in the US. Prior to joining Radius Health, Dr. Hanley served in various roles of increasing responsibility, including Senior Director, Global Pharmaceutical Development at The Medicines Company and Global Program Management roles at each of The Medicines Company, Medarex Inc. and Schering AG. Dr. Hanley began his career in CMC development at Berlex Laboratories / Schering A.G. in the US and in Europe.

Dr. Hanley received his bachelor’s degree in chemistry from Virginia Commonwealth University. He earned a doctorate in physical and analytical chemistry from University of Utah. He has authored multiple peer-reviewed publications, conference presentations, and patents.

About BioXcel Therapeutics, Inc.:
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of BXCL701, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BioXcel’s current expectations and various assumptions. BioXcel believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. BioXcel may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption “Risk Factors” in BioXcel’s 10 Q for the Quarter ended June 30, 2018 and BioXcel’s other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as BioXcel’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. BioXcel cannot guarantee future results, events, levels of activity, performance or achievements. BioXcel does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Contact Information:
The Ruth Group
Lee Roth/ Janhavi Mohite
646-536-7012/ 7026

Source: BioXcel Therapeutics, Inc.